FAAH Pharma Nets Venture Capital Investment
Thursday, August 14, 2014 5:45:00 AM PDT | VentureDeal
Montréal, Canada -- Pharmaceutical technology company FAAH Pharma has secured an undisclosed amount of venture capital investment.
FAAH is developing a compound to treat postherpetic neuralgia.
TVM Capital made the investment.
Specific proceeds purposes were not disclosed, however the company appears to be ready to begin Phase 2a trials of its lead compound.
Email Page | Print Page